NEW YORK, May 14, 2021 /PRNewswire/ — Mind Medicine (MindMed) Inc. (“MindMed” or the “Company”) (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading psychedelic medicine biotech company, has announced its quarterly financial results for the quarter ended March 31, 2021. Q1 2021 Financial Highlights (in USD) Total assets as of March 31, 2021 were $201 million, including $160 million in cash Net Cash…


Previous articlePTSF59 – Bipolar and Psychedelics, with Benjamin Mudge
Next articleMindMed Receives FDA Type C Meeting Response for Project Lucy Phase 2b Clinical Trial